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Background
Fixed wire angioplasty systems1,2 were introduced in the era of
balloon angioplasty as these systems had a lower profile than the
bulky, stiff, over-the-wire systems in use at the time. The fixed wire
system allowed treatment of more complex lesions. As stenting
procedures evolved in the mid 1990s, balloon catheters became
mostly relegated to the pre- and post-dilatation of deployed stents
which accelerated the use of over-the-wire devices. During this
period, stent design and materials had not advanced sufficiently to
provide low enough crossing profiles for direct stenting. The need to
re-cross a lesion to permit further treatment with a stent and
another balloon catheter represented a significant limitation of the
fixed-wire balloon system. Reports of wire fractures and difficulties
with balloon deflations with one of the manufactures systems (USCI
Probe) may also have dampened enthusiasm for these early fixed-
wire systems.3-5 These early limitations of the technology, along with
the development of lower profile over-the-wire systems, resulted in
the limited use of the fixed-wire balloon catheter in recent years.
The Svelte stent-on-a-wire (SOAW) system represents the next
generation of fixed wire technology and is unique in that it has a
direct stenting indication by design.
A direct stenting strategy offers the possibility of further reducing the
risk of adverse events in high risk percutaneous coronary
intervention (PCI) patients, decreasing radiation dose to the
operator and patient, and decreasing procedural time and cost.6-10
Device description
The Svelte SOAW System is a high-performance coronary stent
delivery system, consisting of a balloon expandable Svelte Stent
pre-mounted on the Svelte SOAW single lumen fixed-wire delivery
catheter platform (Figure 1). The Svelte Stent is a thin, flexible,
bare-metal, L605 cobalt chromium coronary stent. The SOAW
delivery catheter has a working length of 145 cm; the device
includes a proximal stainless steel shaft with two proximal shaft
markers (90 cm and 100 cm) to indicate the relative position of the
delivery system to the end of a brachial or femoral guiding catheter;
a flexible distal shaft, a nylon balloon with proximal and distal
radiopaque markers located underneath to indicate the working
length of the balloon and the expanded stent under fluoroscopy; a
spring coil tip, proximal and distal Balloon Control Bands (BCBs) at
each end of the balloon to protect leading stent edges from damage
during delivery, as well as control balloon expansion and deflation; a
standard luer fitting, and an integrated torque device located on the
proximal shaft. (Figure 1)
The SOAW System devices are compatible with 5 Fr guide
catheters. The 0.74 mm (0.029”) profile, leading tip diameter of
0.30 mm (0.012”), and excellent 1.1:1 torque response allows
delivery to distal and tortuous anatomy. The stent reaches nominal
size and is deployed at a balloon inflation pressure of 10-11 atm
with a rated burst pressure at 18 atm. The SOAW System will be
available in 25 models with diameters of 2.5 mm, 2.75 mm,
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3.0 mm, 3.5 mm, and 4.0 mm and lengths of 8 mm, 13 mm,
18 mm, 23 mm, and 28 mm.
Technical specifications
Material: L-605 cobalt chromium alloy
Stent lengths: 8 mm – 28 mm
Balloon diameters: 2.50 to 4.0 mm.
Guide catheter compatibility: 5 Fr (minimum ID 0.056”)
Lesion entry profile: 0.30 mm (0.012”)
Crimped stent profile: 0.74 mm (0.029”)
Working catheter length: 145 cm
Shaft markers: 90 cm and 100 cm
Balloon: Proximal and distal radio-opaque markers; control bands
at each end
Strut thickness: 84 μm
Length of the wire distal to the stent: 22 mm
Indications for use
– Elective direct stenting of a single stenotic lesion in a native
coronary artery.
– Reference vessel ≥ 2.5 mm and ≤4.0 mm in diameter.
– Target lesion < 25 mm in length (the intention should be to cover
the entire lesion with one stent of adequate length).
– Target lesion stenosis ≥ 50% and < 100%.
– Ability to cross the lesion with a wire.
The main exclusion criteria for the use of this device are:
– Target vessel excessively tortuous (two bends > 90˚ to reach the
target lesion).
– Lesion location that is aorto-ostial or within 5 mm of the origin of
the LAD or LCX.
– Target lesion with side branches > 2.0 mm in diameter.
– Target lesion severely calcified.
– Target lesions that are likely to prevent complete inflation of an
angioplasty balloon or proper placement of the stent or stent
delivery system.
Tips and tricks for delivery
It is important to ensure the system is disconnected from the
inflation device as the stent is being tracked through the vessel and
across the lesion. If the inflation device is attached, it will negatively
impact the torque response of the device as it will act as an anchor
when steering into the vessel. Once the stent is in position the
inflation device can be attached and the stent can be deployed
according to the instructions for use.
It is important to torque the device and get a feel for the torque
response when it exits the guiding catheter. Therefore when the wire
tip exits the guide, the catheter shaft can be rotated in order to
confirm the appropriate rotation of the catheter tip.
If the tip of the device is not rotating one should make sure the
torquer is tight on the shaft of the SOAW system. The device can
also be rotated at the hub to check the torque control of the tip.
If it is needed to cross the deployed stent with a guidewire, it is best
to prolapse the tip of the wire prior to crossing the stent to insure the
wire goes through the centre of the stent and not between the struts.
When the stent has been fully deployed, it is recommended to push
the balloon just distal to the lesion and then make a final angiogram
to check result. By doing so, re-crossing the stent if needed with
another device is simplified. It is also possible to post-dilate the
lesion with the SOAW if required.
Pre-clinical studies and initial clinical
experience
The Svelte SOAW System has been evaluated against the MultiLink
Vision (Abbott Vascular, Santa Clara, CA, USA) system in both 
non-good laboratory practice (GLP) and GLP pre-clinical
assessments. These studies relied on porcine models, specifically
Yorkshire pigs, with no gender bias. The Svelte SOAW performed
equivalently to the MultiLink Vision stent with respect to
deliverability and ease of use.
Static x-ray images of implanted stents demonstrate the similarity
between the Svelte and MultiLink Vision stents, as can be seen in
the Figure 2. These images were captured by Svelte Medical
Systems, Inc. after the stents were implanted in coronary arteries of
porcine models. The imaging system is a Faxitron #43855B,
(Faxitron X-Ray LLC, Lincolnshire, IL, USA) and the images were
captured through a 45 s exposure at 45 kV. (Figure 2)
In a recently completed GLP study, eight juvenile Yorkshire swine
(30 day cohort) and seven Yucatan mini-swine (90 day cohort) were
implanted with either Svelte SOAW or control MultiLink Vision
balloon expandable stents. Stented vessels were examined for
standard histomorphmometric and histopathologic measures of
tissue response. Scanning electron microscopy (SEM) was also
conducted to assess endothelialisation.
Figure 1. Device description. Panel A shows the whole device system
with the proximal shaft of the delivery catheter showing at the end a
torquing device and a standard luer fitting (arrows). The stent with the
balloon crimped on the wire (circle) are shown in detail in panel B.
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B
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Histopathological assessment demonstrated minimal injury and
inflammation at both 30 and 90 days with Svelte SOAW and
MultiLink Vision stents. Endothelialisation was complete by 30 days
for both stent treatments as was neointimal maturation (Figure 3).
Histomorphometry demonstrated no differences between Svelte
SOAW and MultiLink Vision stents in neointimal growth, lumen area,
percent occlusion, or wall area ratios at either 30 or 90 days post
implant (Figure 4). SEM analysis of both stents showed 100%
confluent mixture of polygonal and spindle shaped endothelial cells
with minimal inter-cellular spacing at 30 days and cobblestone-like
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Figure 2. Static x-ray images of implanted stents showing the similarity
between the Svelte and MultiLink Vision stents. A) ∅2.5 mm 18 mm
long Svelte stent. B) ∅2.75 mm 18 mm long MultiLink Vision. C)
Single image containing a MultiLink Vision stent (ML-V) and a Svelte
stent (Sv). The imaging system is a Faxitron #43855B, the images
were captured through a 45 s exposure at 45 kV after the stents were
implanted in coronary arteries of porcine models.
Figure 3. Histopathological images demonstrating minimal injury and inflammation at both 30 and 90 days with Svelte SOAW and ML Vision
stents. RCA, right coronary artery.
Figure 4. Histomorphic results demonstrating no differences between
Svelte SOAW and ML Vision stents in neointimal growth, lumen area,
percent occlusion, or wall area ratios at either 30 or 90 days post
implant in porcine coronary arteries.
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polygonal endothelial cells with tight junctions by 90 days
(Figure 5).
Based on the animal studies findings, a prospective, single arm,
first-in-man, multicentre study is on going at Thoraxcenter Erasmus
MC, Rotterdam, The Netherlands. The first-in-man implantation of
the device has recently been performed in a patient with a mid-left
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circumflex coronary artery lesion. The 3-D quantitative coronary
angiogram (QCA) pre- and post-stenting, and the 3-D optical
coherence tomography (OCT) post-stenting are shown in Figure 6
(A, B) and Figure 7. The 3-D angiographic reconstruction with
virtual navigation through the centreline of the vessel and the
coronary angiogram showing the positioning of the device through
the lesion is displayed on www.eurointervention.com.
Conclusions
The Svelte SOAW system represents the next generation iteration of
fixed wire technology, and is unique in that it has a direct stenting
indication by design.
Figure 5. Scanning electron microscopy (SEM) of vessels implanted with either Svelte SOAW or ML Vision stents showing 100% confluent mixture
of polygonal and spindle shaped endothelial cells with minimal inter-cellular spacing at 30 days and cobblestone-like polygonal endothelial cells
with tight junctions by 90 days.
Figure 6. A) 3-D quantitative coronary angiogram, QCA pre-stenting. B) 3-D QCA post-stenting.
Figure 7. 3-D optical coherence tomography (OCT) post-stenting
showing well apposed Svelte stent struts.
C_413_Sarno_AOPapril  12/07/10  11:01  Page416
- 417 -
It may enable a further reduction in procedure time, contrast use
and cost compared to conventional devices.
Results from a GLP study demonstrate an acceptable healing
response when the Svelte SOAW is implanted in porcine coronary
arteries with complete endothelialisation by 30 days that was no
different than that observed with the MultiLink Vision stent.
The potential downsizing of sheath sizes and improved outcomes
with direct stenting may make this approach appealing.
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